Your browser doesn't support javascript.
loading
Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor.
Chen, Yuhong; Chen, Junyong; Long, Liansheng; Han, Leng; Mi, Xiaohui; Song, Yanfang; Cheng, Huanqing; Zhang, Yanrui; Cheng, Liyang.
Afiliación
  • Chen Y; Department of General Surgery, the General Hospital of Southern Theater Command, People's Liberation Army (PLA), Guangzhou, China.
  • Chen J; Department of General Surgery, the General Hospital of Southern Theater Command, People's Liberation Army (PLA), Guangzhou, China.
  • Long L; Department of General Surgery, the General Hospital of Southern Theater Command, People's Liberation Army (PLA), Guangzhou, China.
  • Han L; Department of Pathology, The General Hospital of Southern Theater Command, People's Liberation Army (PLA), Guangzhou, China.
  • Mi X; Medical Affairs Department, Acornmed Biotechnology Co., Ltd, Beijing, China.
  • Song Y; Medical Affairs Department, Acornmed Biotechnology Co., Ltd, Beijing, China.
  • Cheng H; Medical Affairs Department, Acornmed Biotechnology Co., Ltd, Beijing, China.
  • Zhang Y; Medical Affairs Department, Acornmed Biotechnology Co., Ltd, Beijing, China.
  • Cheng L; Department of General Surgery, the General Hospital of Southern Theater Command, People's Liberation Army (PLA), Guangzhou, China.
Front Oncol ; 13: 1260706, 2023.
Article en En | MEDLINE | ID: mdl-38023229
In this report, we present a case study of a 64-year-old female who was diagnosed with gastrointestinal stromal tumors (GISTs) and subsequently developed liver metastases despite undergoing radical resection. Next-generation sequencing (NGS) assays indicated that the tumor lacked KIT/PDGFRA/SDH/RAS-P (RAS pathways, RAS-P) mutations, thereby classifying this patient as quadruple WT GIST (qGIST). Treatment with imatinib was initiated, and after 2.5 months, recurrence of the tumor and multiple metastases around the surgical site were observed. Consequently, the patient was switched to sunitinib treatment and responded well. Although she responded well to sunitinib, the patient died of tumor dissemination within 4 months. This case study highlights the potential efficacy of imatinib and the VEGFR-TKI sunitinib in treating qGIST patients harboring a TP53 missense mutation.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza